I Love Lund (LOVE) Q1 2026 earnings summary

Executive summary

• Focused on supporting innovative, early-stage companies in Lund, with over 600 shareholders and a diversified portfolio of around 50 holdings, mainly unlisted growth companies.

• No new investments in Q1 2026; emphasis on follow-on investments in existing portfolio companies such as LifeFinder, Uman Sense, and Strominnate.

• Notable divestments in listed holdings (Camurus, Alfa Laval, Beammwave) to rebalance towards unlisted assets and prepare for new investments.

• Saga Diagnostics, a portfolio company, was acquired by Foundation Medicine (Roche), expected to yield a significant cash gain for shareholders.

• Strong shareholder engagement, with a well-attended AGM and new board members with capital market experience.

Financial highlights

• Net sales for Q1 2026 were SEK 300 (0 in Q1 2025).

• Operating result was SEK -837,000 (SEK -758,000 in Q1 2025).

• Net result after financial items improved to SEK -440,000 (SEK -4,234,000 in Q1 2025), reflecting lower write-downs.

• Earnings per share were SEK -1 (SEK -9.8 in Q1 2025).

• Equity per share at period end was SEK 81.9 (SEK 83.2 in Q1 2025); net asset value per share was SEK 103.2.

• Cash flow from divestments in listed holdings amounted to SEK 1,861,343.

• Cash and cash equivalents at period end were SEK 1,126,553.

Outlook and guidance

• Management notes increased optimism in the market for innovative startups, with expectations of a shift from risk aversion to risk appetite in 2026.

• No formal financial forecasts are provided.